Ventas Announces R&I Development Commitments Worth $0.8B
Zacks Investment Research | Jun 19, 2019 07:34AM ET
Ventas, Inc. (NYSE:VTR) recently announced four new developments, totaling approximately $0.8 billion in its university-based Research & Innovation (R&I) segment. These investments are part of the $1.5-billion R&I investment pipeline announced by the company this February.
All the projects were announced in partnership with Wexford Science & Technology, LLC — a well-known developer of university-focused real estate solutions. The developments consist of two projects in the Philadelphia University City (uCity) submarket — a new development in association with the University of Pennsylvania and The College of Nursing and Health Professions, Drexel University — totaling $400 million.
It also includes the Pitt immune transplant and therapy center with the University of Pittsburgh as well as expansion of the dynamic Cortex Innovation Community, along with Washington University in St. Louis. The projects are expected to open in 2021-2022.
With the previously-announced development at Arizona State University, Ventas has commitment to its R&I pipeline amounts to $0.9 billion. These projects expand the company’s R&I portfolio by 1.5 million square feet and are 40% pre-leased. Further, it is anticipated to drive value accretion at stabilization, with unlevered cash yield of more than 7% and GAAP yield of more than 8%.
Notably, such investments offer Ventas the opportunity to capitalize on the growing healthcare-driven research and development, supported by top-tier research universities. In fact, pro forma for announced developments, the company’s R&I portfolio will span approximately eight million square feet and likely generate around $230 million in annual net operating income, when the projects stabilize.
Furthermore, with relationships with more than 15 leading research universities in its R&I portfolio, the company is well poised to cater the rapidly aging population.
Over the past three months, shares of this Zacks Rank #3 (Hold) company have rallied 11.3% compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.